 MARLBOROUGH, Mass. , April 18, 2022 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced that in vivo data showing PH-762 administered locally clears untreated distal tumors, indicating a systemic immune response was selected for an encore presentation at the Society for Immunotherapy of Cancer SITC Tumor Immune Microenvironment: A Holistic Approach Workshop, which is being held April 21 st 22nd in San Diego and virtually. 